Skip to main content
. Author manuscript; available in PMC: 2014 Oct 17.
Published in final edited form as: N Engl J Med. 2014 Feb 20;370(8):699–708. doi: 10.1056/NEJMoa1308573

Figure 2. Primary End Points, According to Study Group.

Figure 2

The median rates of overall survival were similar in the bevacizumab and placebo groups (Panel A). The median rate of progression-free survival was higher in the bevacizumab group than in the placebo group but did not reach the prespecified threshold for significance (P<0.004) (Panel B).